Edward Dempsey
Concepts (333)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neprilysin | 6 | 2017 | 47 | 2.460 |
Why?
| Muscle, Smooth, Vascular | 22 | 2017 | 420 | 2.360 |
Why?
| Pulmonary Artery | 26 | 2020 | 1031 | 1.850 |
Why?
| Protein Kinase C | 15 | 2007 | 274 | 1.830 |
Why?
| Hypoxia | 18 | 2021 | 937 | 1.380 |
Why?
| rho GTP-Binding Proteins | 2 | 2020 | 62 | 1.260 |
Why?
| Pulmonary Circulation | 7 | 2009 | 407 | 1.000 |
Why?
| Isoenzymes | 9 | 2007 | 285 | 0.750 |
Why?
| Hypertension, Pulmonary | 12 | 2021 | 1749 | 0.730 |
Why?
| Lung | 11 | 2021 | 3672 | 0.700 |
Why?
| Evans Blue | 1 | 2018 | 6 | 0.640 |
Why?
| Capillary Permeability | 1 | 2018 | 138 | 0.610 |
Why?
| Cell Division | 25 | 2009 | 759 | 0.580 |
Why?
| Protein Kinase C-epsilon | 3 | 2005 | 26 | 0.570 |
Why?
| Myocytes, Smooth Muscle | 2 | 2019 | 239 | 0.560 |
Why?
| Muscle Proteins | 1 | 2017 | 209 | 0.530 |
Why?
| Blood Vessels | 3 | 2016 | 181 | 0.510 |
Why?
| Endothelium, Vascular | 2 | 2020 | 845 | 0.450 |
Why?
| Aging | 4 | 2020 | 1631 | 0.440 |
Why?
| Animals | 44 | 2021 | 32102 | 0.440 |
Why?
| Mice, Knockout | 6 | 2017 | 2604 | 0.430 |
Why?
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2013 | 24 | 0.430 |
Why?
| Animals, Newborn | 10 | 2007 | 780 | 0.390 |
Why?
| Airway Remodeling | 1 | 2010 | 60 | 0.360 |
Why?
| Pulmonary Disease, Chronic Obstructive | 3 | 2017 | 1098 | 0.320 |
Why?
| Cattle | 16 | 2002 | 935 | 0.300 |
Why?
| Fibroblasts | 7 | 2019 | 839 | 0.290 |
Why?
| Mice | 14 | 2018 | 15052 | 0.290 |
Why?
| Endothelin-1 | 2 | 2017 | 167 | 0.250 |
Why?
| Protein Kinases | 1 | 2007 | 306 | 0.250 |
Why?
| Signal Transduction | 7 | 2020 | 4541 | 0.250 |
Why?
| Lung Neoplasms | 11 | 2012 | 2207 | 0.240 |
Why?
| Enzyme Activation | 5 | 2017 | 793 | 0.230 |
Why?
| rho-Associated Kinases | 2 | 2019 | 81 | 0.220 |
Why?
| Cells, Cultured | 12 | 2017 | 3914 | 0.210 |
Why?
| Vascular Remodeling | 2 | 2021 | 151 | 0.210 |
Why?
| Lung Diseases | 2 | 2007 | 710 | 0.210 |
Why?
| Mice, Inbred C57BL | 5 | 2017 | 4773 | 0.210 |
Why?
| Insulin-Like Growth Factor I | 3 | 1997 | 281 | 0.210 |
Why?
| Potassium Channels, Voltage-Gated | 1 | 2002 | 48 | 0.210 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2012 | 88 | 0.210 |
Why?
| Cell Movement | 3 | 2017 | 867 | 0.200 |
Why?
| Vasoconstriction | 1 | 2002 | 185 | 0.190 |
Why?
| Growth Substances | 4 | 1997 | 136 | 0.190 |
Why?
| Tetradecanoylphorbol Acetate | 5 | 1997 | 153 | 0.190 |
Why?
| Butyrates | 1 | 2021 | 53 | 0.190 |
Why?
| Proto-Oncogene Proteins c-myc | 2 | 2020 | 114 | 0.190 |
Why?
| Metabolic Diseases | 1 | 2021 | 99 | 0.180 |
Why?
| Phenotype | 5 | 2017 | 2829 | 0.180 |
Why?
| Mitogens | 2 | 1997 | 58 | 0.180 |
Why?
| Forkhead Box Protein O3 | 1 | 2020 | 13 | 0.180 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2021 | 192 | 0.170 |
Why?
| Platelet-Derived Growth Factor | 3 | 1997 | 82 | 0.170 |
Why?
| Vasa Vasorum | 1 | 2020 | 33 | 0.170 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2020 | 146 | 0.170 |
Why?
| rhoA GTP-Binding Protein | 1 | 2019 | 75 | 0.160 |
Why?
| Cellular Microenvironment | 1 | 2019 | 78 | 0.160 |
Why?
| Genotype | 2 | 2017 | 1786 | 0.160 |
Why?
| Metabolome | 1 | 2021 | 287 | 0.160 |
Why?
| Pulmonary Alveoli | 2 | 2012 | 376 | 0.160 |
Why?
| Thymidine | 5 | 1996 | 58 | 0.150 |
Why?
| ets-Domain Protein Elk-1 | 1 | 2017 | 13 | 0.150 |
Why?
| Smooth Muscle Myosins | 1 | 2017 | 7 | 0.150 |
Why?
| Kruppel-Like Transcription Factors | 1 | 2017 | 61 | 0.150 |
Why?
| Actins | 3 | 2017 | 383 | 0.140 |
Why?
| Microfilament Proteins | 1 | 2017 | 126 | 0.140 |
Why?
| Vascular Diseases | 1 | 2019 | 230 | 0.140 |
Why?
| Calcium-Binding Proteins | 1 | 2017 | 203 | 0.140 |
Why?
| Substance P | 1 | 2016 | 44 | 0.130 |
Why?
| Chronic Disease | 6 | 2009 | 1598 | 0.130 |
Why?
| Doxycycline | 1 | 2016 | 56 | 0.130 |
Why?
| Duodenum | 1 | 2016 | 63 | 0.130 |
Why?
| Pneumonia | 1 | 2021 | 576 | 0.130 |
Why?
| Neovascularization, Pathologic | 5 | 2020 | 283 | 0.130 |
Why?
| Sleep Apnea Syndromes | 2 | 2013 | 74 | 0.130 |
Why?
| Uterus | 3 | 2006 | 193 | 0.120 |
Why?
| Humans | 30 | 2021 | 115587 | 0.120 |
Why?
| Carcinogens | 2 | 2012 | 105 | 0.120 |
Why?
| Cell Communication | 1 | 1996 | 282 | 0.120 |
Why?
| In Vitro Techniques | 5 | 2007 | 1044 | 0.120 |
Why?
| Myocardium | 1 | 2019 | 926 | 0.120 |
Why?
| Sputum | 3 | 2005 | 290 | 0.120 |
Why?
| Endothelial Cells | 3 | 2021 | 695 | 0.110 |
Why?
| Estradiol | 2 | 1997 | 452 | 0.110 |
Why?
| Enzyme Inhibitors | 4 | 2002 | 757 | 0.110 |
Why?
| Cell Proliferation | 2 | 2017 | 2194 | 0.110 |
Why?
| Gene Expression Regulation, Developmental | 1 | 1997 | 794 | 0.110 |
Why?
| Piperidines | 2 | 2012 | 163 | 0.100 |
Why?
| Blotting, Western | 3 | 2012 | 1153 | 0.100 |
Why?
| Quinazolines | 2 | 2012 | 241 | 0.100 |
Why?
| Gene Expression Regulation | 3 | 2016 | 2353 | 0.100 |
Why?
| Mice, Transgenic | 1 | 2016 | 1970 | 0.090 |
Why?
| Gene Expression Regulation, Enzymologic | 2 | 2005 | 274 | 0.090 |
Why?
| Bronchoscopy | 5 | 2009 | 245 | 0.090 |
Why?
| DNA Primers | 2 | 2009 | 514 | 0.090 |
Why?
| Somatomedins | 1 | 1990 | 29 | 0.090 |
Why?
| Cardiovascular Diseases | 1 | 2021 | 1724 | 0.090 |
Why?
| Carcinoma in Situ | 3 | 2005 | 44 | 0.090 |
Why?
| Arteries | 2 | 2006 | 250 | 0.090 |
Why?
| Precancerous Conditions | 3 | 2004 | 156 | 0.090 |
Why?
| Maleimides | 3 | 2000 | 24 | 0.090 |
Why?
| Biomarkers | 1 | 2020 | 3466 | 0.080 |
Why?
| Isotretinoin | 1 | 2009 | 22 | 0.080 |
Why?
| Blood Pressure | 3 | 2021 | 1537 | 0.080 |
Why?
| Tocopherols | 1 | 2009 | 22 | 0.080 |
Why?
| ErbB Receptors | 1 | 2012 | 557 | 0.080 |
Why?
| Cell Hypoxia | 3 | 1999 | 220 | 0.080 |
Why?
| Biomarkers, Tumor | 3 | 2012 | 1048 | 0.080 |
Why?
| Female | 17 | 2012 | 59913 | 0.080 |
Why?
| Carcinoma, Squamous Cell | 2 | 2005 | 577 | 0.070 |
Why?
| Male | 10 | 2018 | 55949 | 0.070 |
Why?
| Indoles | 3 | 2000 | 309 | 0.070 |
Why?
| Galectin 1 | 1 | 2006 | 2 | 0.070 |
Why?
| Bronchi | 2 | 2000 | 250 | 0.070 |
Why?
| Heart Failure | 1 | 2019 | 1963 | 0.070 |
Why?
| Genes, ras | 2 | 1997 | 91 | 0.070 |
Why?
| Hyperoxia | 1 | 2007 | 97 | 0.070 |
Why?
| Videotape Recording | 1 | 2006 | 30 | 0.070 |
Why?
| Thiazolidinediones | 1 | 2006 | 143 | 0.060 |
Why?
| Rats, Sprague-Dawley | 3 | 2021 | 2262 | 0.060 |
Why?
| Disease Models, Animal | 2 | 2013 | 3580 | 0.060 |
Why?
| Smoking | 4 | 2009 | 1457 | 0.060 |
Why?
| Hypertrophy, Right Ventricular | 2 | 2021 | 142 | 0.060 |
Why?
| DNA | 4 | 1997 | 1356 | 0.060 |
Why?
| Rats | 4 | 2021 | 5034 | 0.060 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2005 | 160 | 0.060 |
Why?
| Blood | 2 | 1995 | 97 | 0.060 |
Why?
| Nitric Oxide Synthase Type III | 1 | 2005 | 185 | 0.060 |
Why?
| Calcium | 2 | 2002 | 1103 | 0.060 |
Why?
| Endothelins | 2 | 1996 | 61 | 0.060 |
Why?
| Drug Synergism | 3 | 1996 | 317 | 0.060 |
Why?
| Hemodynamics | 1 | 2009 | 968 | 0.060 |
Why?
| Drug Delivery Systems | 1 | 2007 | 301 | 0.060 |
Why?
| Guinea Pigs | 3 | 2006 | 151 | 0.060 |
Why?
| Bronchoalveolar Lavage Fluid | 2 | 1997 | 608 | 0.060 |
Why?
| Case-Control Studies | 1 | 2010 | 3022 | 0.060 |
Why?
| Fetus | 2 | 1997 | 702 | 0.050 |
Why?
| Shaw Potassium Channels | 1 | 2002 | 4 | 0.050 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2005 | 388 | 0.050 |
Why?
| Potassium Chloride | 1 | 2002 | 35 | 0.050 |
Why?
| Stem Cells | 1 | 2007 | 546 | 0.050 |
Why?
| Potassium Channel Blockers | 1 | 2002 | 29 | 0.050 |
Why?
| Angiotensin II | 1 | 2002 | 91 | 0.050 |
Why?
| Potassium Channels | 1 | 2002 | 121 | 0.050 |
Why?
| Nitric Oxide Synthase | 1 | 2002 | 213 | 0.050 |
Why?
| Antineoplastic Agents | 2 | 2010 | 1893 | 0.050 |
Why?
| Tunica Media | 2 | 1998 | 35 | 0.050 |
Why?
| Urethane | 2 | 2012 | 41 | 0.050 |
Why?
| Protein Kinase C beta | 2 | 2000 | 24 | 0.050 |
Why?
| Macrophages | 2 | 2021 | 1284 | 0.050 |
Why?
| Gene Deletion | 1 | 2002 | 355 | 0.050 |
Why?
| Systole | 1 | 2021 | 169 | 0.050 |
Why?
| Patient Education as Topic | 1 | 2006 | 686 | 0.050 |
Why?
| Aged | 6 | 2010 | 19251 | 0.050 |
Why?
| Fluorescence | 1 | 2001 | 154 | 0.050 |
Why?
| Tight Junctions | 1 | 2021 | 68 | 0.050 |
Why?
| Microvessels | 1 | 2021 | 68 | 0.050 |
Why?
| Acetylation | 1 | 2021 | 212 | 0.050 |
Why?
| Genetic Predisposition to Disease | 1 | 2009 | 2125 | 0.050 |
Why?
| Receptors, Purinergic P2Y | 1 | 2020 | 7 | 0.040 |
Why?
| Nitric Oxide | 1 | 2005 | 832 | 0.040 |
Why?
| Cytokines | 2 | 2021 | 1853 | 0.040 |
Why?
| Ligands | 1 | 2021 | 569 | 0.040 |
Why?
| Neoplasms | 1 | 2013 | 2118 | 0.040 |
Why?
| GTPase-Activating Proteins | 1 | 2019 | 71 | 0.040 |
Why?
| Guanine Nucleotide Exchange Factors | 1 | 2019 | 56 | 0.040 |
Why?
| Trans-Activators | 1 | 2001 | 370 | 0.040 |
Why?
| Light | 1 | 2001 | 337 | 0.040 |
Why?
| Up-Regulation | 1 | 2021 | 820 | 0.040 |
Why?
| Oxygen | 1 | 2002 | 837 | 0.040 |
Why?
| Immune System | 1 | 2019 | 173 | 0.040 |
Why?
| Leukocytes | 1 | 2019 | 281 | 0.040 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2020 | 332 | 0.040 |
Why?
| Aorta | 2 | 2001 | 353 | 0.040 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 400 | 0.040 |
Why?
| Middle Aged | 5 | 2010 | 26999 | 0.040 |
Why?
| Adenosine Triphosphate | 1 | 2020 | 431 | 0.040 |
Why?
| Culture Media, Serum-Free | 1 | 1997 | 42 | 0.040 |
Why?
| Disease Susceptibility | 1 | 2019 | 316 | 0.040 |
Why?
| Proto-Oncogene Proteins c-sis | 1 | 1997 | 35 | 0.040 |
Why?
| Ischemia | 1 | 2000 | 363 | 0.040 |
Why?
| Protein Kinase C-alpha | 1 | 1997 | 41 | 0.040 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2020 | 362 | 0.040 |
Why?
| Organ Specificity | 1 | 1997 | 273 | 0.040 |
Why?
| Nuclear Proteins | 1 | 2001 | 594 | 0.040 |
Why?
| Sensitivity and Specificity | 2 | 2001 | 1718 | 0.040 |
Why?
| Pregnancy, Animal | 1 | 1997 | 52 | 0.040 |
Why?
| Muscle Development | 1 | 1997 | 93 | 0.030 |
Why?
| Bronchial Neoplasms | 1 | 1996 | 14 | 0.030 |
Why?
| Reactive Oxygen Species | 1 | 2019 | 549 | 0.030 |
Why?
| Microcirculation | 2 | 2007 | 138 | 0.030 |
Why?
| Heart Ventricles | 1 | 2021 | 712 | 0.030 |
Why?
| Species Specificity | 1 | 1997 | 552 | 0.030 |
Why?
| Rabbits | 1 | 1997 | 752 | 0.030 |
Why?
| Blood Physiological Phenomena | 1 | 1996 | 14 | 0.030 |
Why?
| Point Mutation | 1 | 1997 | 217 | 0.030 |
Why?
| Tritium | 1 | 1996 | 69 | 0.030 |
Why?
| Receptors, Platelet-Derived Growth Factor | 1 | 1996 | 13 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 2 | 2010 | 1870 | 0.030 |
Why?
| Neoplasms, Second Primary | 1 | 1997 | 91 | 0.030 |
Why?
| Exercise | 1 | 2006 | 1609 | 0.030 |
Why?
| Rats, Inbred Strains | 1 | 1996 | 376 | 0.030 |
Why?
| Myocytes, Cardiac | 1 | 2019 | 457 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 1996 | 372 | 0.030 |
Why?
| Young Adult | 1 | 2010 | 10470 | 0.030 |
Why?
| Protein Precursors | 1 | 1996 | 119 | 0.030 |
Why?
| Quality of Life | 1 | 2006 | 2385 | 0.030 |
Why?
| Clinical Trials as Topic | 1 | 2019 | 941 | 0.030 |
Why?
| Catalysis | 1 | 1995 | 299 | 0.030 |
Why?
| Subcellular Fractions | 1 | 1994 | 78 | 0.030 |
Why?
| Models, Biological | 1 | 2021 | 1646 | 0.030 |
Why?
| Flow Cytometry | 2 | 1996 | 1083 | 0.030 |
Why?
| Adenosine Diphosphate | 1 | 1994 | 81 | 0.030 |
Why?
| Stress, Mechanical | 1 | 1996 | 440 | 0.030 |
Why?
| Recombinant Proteins | 1 | 1997 | 1243 | 0.030 |
Why?
| Poly I-C | 1 | 1994 | 52 | 0.030 |
Why?
| Blood Proteins | 1 | 1996 | 238 | 0.030 |
Why?
| Risk Factors | 5 | 2009 | 8697 | 0.030 |
Why?
| Endothelin Receptor Antagonists | 1 | 1993 | 58 | 0.030 |
Why?
| Hyperplasia | 2 | 2006 | 166 | 0.030 |
Why?
| Neoplasm Proteins | 1 | 1996 | 385 | 0.030 |
Why?
| Receptors, Estrogen | 1 | 1996 | 372 | 0.030 |
Why?
| Complement Factor B | 1 | 1994 | 100 | 0.030 |
Why?
| Extracellular Matrix | 2 | 2006 | 439 | 0.030 |
Why?
| Serotonin | 1 | 1994 | 296 | 0.030 |
Why?
| Methylcholanthrene | 1 | 2012 | 18 | 0.030 |
Why?
| Butylated Hydroxytoluene | 1 | 2012 | 32 | 0.030 |
Why?
| Adolescent | 1 | 2010 | 17889 | 0.030 |
Why?
| Pregnancy | 3 | 2006 | 5548 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 193 | 0.020 |
Why?
| Time Factors | 2 | 2007 | 6165 | 0.020 |
Why?
| Peptides, Cyclic | 1 | 1993 | 262 | 0.020 |
Why?
| Infant, Newborn | 2 | 2007 | 5077 | 0.020 |
Why?
| Blood Platelets | 1 | 1994 | 350 | 0.020 |
Why?
| Apoptosis | 1 | 2000 | 2377 | 0.020 |
Why?
| Phorbol 12,13-Dibutyrate | 1 | 1991 | 9 | 0.020 |
Why?
| Cell Count | 2 | 2006 | 305 | 0.020 |
Why?
| Aerobiosis | 1 | 1991 | 20 | 0.020 |
Why?
| Anaerobiosis | 1 | 1991 | 49 | 0.020 |
Why?
| Dimethyl Sulfoxide | 1 | 1991 | 43 | 0.020 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2012 | 167 | 0.020 |
Why?
| Tumor Cells, Cultured | 3 | 1996 | 850 | 0.020 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2012 | 225 | 0.020 |
Why?
| Protein Binding | 1 | 1996 | 1917 | 0.020 |
Why?
| Chemoprevention | 1 | 2010 | 88 | 0.020 |
Why?
| Biopsy | 2 | 2005 | 1056 | 0.020 |
Why?
| DNA Replication | 1 | 1991 | 203 | 0.020 |
Why?
| Antioxidants | 1 | 2012 | 533 | 0.020 |
Why?
| RNA, Messenger | 1 | 1996 | 2574 | 0.020 |
Why?
| Down-Regulation | 1 | 1990 | 601 | 0.020 |
Why?
| Molecular Targeted Therapy | 1 | 2010 | 348 | 0.020 |
Why?
| Leukocyte Common Antigens | 1 | 2007 | 76 | 0.020 |
Why?
| Kinetics | 1 | 1991 | 1569 | 0.020 |
Why?
| Rats, Inbred WKY | 1 | 2006 | 32 | 0.020 |
Why?
| Elastin | 1 | 2006 | 78 | 0.020 |
Why?
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 63 | 0.020 |
Why?
| Codon | 2 | 1997 | 86 | 0.020 |
Why?
| Aged, 80 and over | 2 | 2009 | 6417 | 0.020 |
Why?
| Serum | 1 | 2006 | 57 | 0.020 |
Why?
| PPAR gamma | 1 | 2006 | 185 | 0.020 |
Why?
| Vascular Resistance | 1 | 2006 | 338 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2006 | 499 | 0.020 |
Why?
| Protein Kinase Inhibitors | 1 | 2010 | 790 | 0.020 |
Why?
| Collagen | 1 | 2006 | 415 | 0.010 |
Why?
| Sheep | 1 | 2006 | 764 | 0.010 |
Why?
| Antibodies, Monoclonal | 1 | 2010 | 1265 | 0.010 |
Why?
| Adenocarcinoma | 1 | 2010 | 799 | 0.010 |
Why?
| Neoplasm Recurrence, Local | 1 | 2009 | 863 | 0.010 |
Why?
| Polymerase Chain Reaction | 2 | 1997 | 1000 | 0.010 |
Why?
| Teaching | 1 | 2006 | 224 | 0.010 |
Why?
| Neoplasm Invasiveness | 1 | 2005 | 445 | 0.010 |
Why?
| Epithelial Cells | 2 | 2001 | 961 | 0.010 |
Why?
| Confidence Intervals | 1 | 2004 | 309 | 0.010 |
Why?
| Vital Capacity | 1 | 2004 | 277 | 0.010 |
Why?
| Activities of Daily Living | 1 | 2006 | 352 | 0.010 |
Why?
| Gestational Age | 1 | 2006 | 757 | 0.010 |
Why?
| Bronchopulmonary Dysplasia | 1 | 2007 | 330 | 0.010 |
Why?
| Base Sequence | 1 | 2006 | 2114 | 0.010 |
Why?
| Forced Expiratory Volume | 1 | 2004 | 516 | 0.010 |
Why?
| Patient Compliance | 1 | 2006 | 524 | 0.010 |
Why?
| CREB-Binding Protein | 1 | 2001 | 27 | 0.010 |
Why?
| Metaplasia | 1 | 2001 | 54 | 0.010 |
Why?
| Adaptation, Psychological | 1 | 2006 | 551 | 0.010 |
Why?
| Single-Blind Method | 1 | 2001 | 255 | 0.010 |
Why?
| Fluorescent Antibody Technique | 1 | 2001 | 398 | 0.010 |
Why?
| Chromosomes, Human, Pair 3 | 1 | 2000 | 49 | 0.010 |
Why?
| Loss of Heterozygosity | 1 | 2000 | 41 | 0.010 |
Why?
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2000 | 57 | 0.010 |
Why?
| Ki-67 Antigen | 1 | 2000 | 104 | 0.010 |
Why?
| Carcinoma | 1 | 2001 | 200 | 0.010 |
Why?
| Fibrosis | 1 | 2002 | 457 | 0.010 |
Why?
| Airway Obstruction | 1 | 2001 | 168 | 0.010 |
Why?
| Prevalence | 1 | 2005 | 2264 | 0.010 |
Why?
| Risk | 1 | 2001 | 819 | 0.010 |
Why?
| Carcinoma, Non-Small-Cell Lung | 2 | 1997 | 963 | 0.010 |
Why?
| Cell Death | 1 | 2000 | 326 | 0.010 |
Why?
| Mitotic Index | 1 | 1997 | 26 | 0.010 |
Why?
| Bromodeoxyuridine | 1 | 1997 | 73 | 0.010 |
Why?
| Cytoskeletal Proteins | 1 | 1997 | 145 | 0.010 |
Why?
| Tunica Intima | 1 | 1997 | 78 | 0.010 |
Why?
| Myosins | 1 | 1997 | 126 | 0.010 |
Why?
| Mammals | 1 | 1999 | 251 | 0.010 |
Why?
| Chromosome Banding | 1 | 1996 | 21 | 0.010 |
Why?
| Ploidies | 1 | 1996 | 17 | 0.010 |
Why?
| Comorbidity | 1 | 2001 | 1473 | 0.010 |
Why?
| Ovariectomy | 1 | 1997 | 117 | 0.010 |
Why?
| Karyotyping | 1 | 1996 | 102 | 0.010 |
Why?
| Ligases | 1 | 1996 | 32 | 0.010 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2000 | 449 | 0.010 |
Why?
| Bronchoalveolar Lavage | 1 | 1996 | 89 | 0.010 |
Why?
| Heparin | 1 | 1997 | 227 | 0.010 |
Why?
| Immunohistochemistry | 1 | 2000 | 1642 | 0.010 |
Why?
| Immunophenotyping | 1 | 1996 | 277 | 0.010 |
Why?
| Transcription, Genetic | 1 | 2001 | 1310 | 0.010 |
Why?
| Regional Blood Flow | 1 | 1997 | 414 | 0.010 |
Why?
| HeLa Cells | 1 | 1996 | 567 | 0.010 |
Why?
| Mass Screening | 1 | 2001 | 1024 | 0.010 |
Why?
| Adult | 2 | 2009 | 30718 | 0.010 |
Why?
| Surveys and Questionnaires | 1 | 2006 | 4665 | 0.010 |
Why?
| Calcimycin | 1 | 1994 | 46 | 0.010 |
Why?
| Epidermal Growth Factor | 1 | 1994 | 161 | 0.010 |
Why?
| Prognosis | 1 | 2001 | 3339 | 0.010 |
Why?
| Interferon-beta | 1 | 1994 | 79 | 0.010 |
Why?
| Mice, Inbred C3H | 1 | 1994 | 244 | 0.010 |
Why?
| Neoplasm Staging | 1 | 1997 | 1178 | 0.010 |
Why?
| Cell Survival | 1 | 1996 | 1024 | 0.010 |
Why?
| Macrophage Activation | 1 | 1994 | 165 | 0.010 |
Why?
| Analysis of Variance | 1 | 1993 | 1227 | 0.010 |
Why?
| Interferon-gamma | 1 | 1994 | 726 | 0.010 |
Why?
| Mutation | 1 | 2000 | 3364 | 0.010 |
Why?
| Peptides | 1 | 1994 | 864 | 0.010 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 1994 | 1137 | 0.000 |
Why?
| Retrospective Studies | 1 | 2005 | 12608 | 0.000 |
Why?
|
|
Dempsey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|